• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms

    2021-12-03 06:15:22CarloRomanoSettanniGianlucaIaniroFrancescaRomanaPonzianiStefanoBibboJonathanPhilipSegalGiovanniCammarotaAntonioGasbarrini
    World Journal of Gastroenterology 2021年43期

    Carlo Romano Settanni, Gianluca Ianiro, Francesca Romana Ponziani, Stefano Bibbo, Jonathan Philip Segal,Giovanni Cammarota, Antonio Gasbarrini

    Abstract In December 2019 a novel coronavirus disease 2019 (COVID-19 ), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 ), started spreading from Wuhan city of Chinese Hubei province and rapidly became a global pandemic. Clinical symptoms of the disease range from paucisymptomatic disease to a much more severe disease. Typical symptoms of the initial phase include fever and cough, with possible progression to acute respiratory distress syndrome. Gastrointestinal manifestations such as diarrhoea, vomiting and abdominal pain are reported in a considerable number of affected individuals and may be due to the SARS-CoV-2 tropism for the peptidase angiotensin receptor 2 .The intestinal homeostasis and microenvironment appear to play a major role in the pathogenesis of COVID-19 and in the enhancement of the systemic inflammatory responses. Long-term consequences of COVID-19 include respiratory disturbances and other disabling manifestations, such as fatigue and psychological impairment. To date, there is a paucity of data on the gastrointestinal sequelae of SARS-CoV-2 infection. Since COVID-19 can directly or indirectly affect the gut physiology in different ways, it is plausible that functional bowel diseases may occur after the recovery because of potential pathophysiological alterations (dysbiosis, disruption of the intestinal barrier, mucosal microinflammation, post-infectious states, immune dysregulation and psychological stress). In this review we speculate that COVID-19 can trigger irritable bowel syndrome and we discuss the potential mechanisms.

    Key Words: SARS-CoV-2 ; COVID-19 ; Irritable bowel syndrome; Microbiota; Dysbiosis;Gut-brain axis

    INTRODUCTION

    In December 2019 a cluster of acute atypical respiratory infections were reported in the Wuhan city of Hubei province by the Chinese authorities to the World Health Organization (WHO). The responsible pathogen was identified as a new member of the family Coronaviridae, and it was called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 ) due to its similarity to the SARS coronavirus, previously involved in the 2002 -2003 pandemic. The SARS-CoV-2 -related disease was named coronavirus disease 2019 (COVID-19 ) and rapidly spread worldwide. Indeed, COVID-19 became a public health emergency on January 30 , 2020 and, subsequently, a pandemic state was declared on March 11 , 2020 by the WHO[1].

    SARS-CoV-2 is a positive-sense single-stranded RNA virus, whose genome encodes for four major structural proteins: Spike (S) protein, envelope protein, membrane protein and nucleocapsid protein. The S protein mediates the entering of SARS-CoV-2 in the host cells by binding to the peptidase angiotensin receptor 2 (ACE2 )[2].

    COVID-19 is a contagious and highly lethal illness, especially for individuals with chronic comorbidities (such as diabetes mellitus, hypertension, cardiorespiratory disorders, chronic hepatic and renal diseases), elderly, oncological and immunosuppressed patients[2]. The infection is predominately transmitted by person to person through respiratory droplets, although many other modes of potential transmission have been postulated, which include through faecal-oral transmission. The average incubation period for COVID-19 is 5 .2 d, but it can last up to 15 .5 d.

    The infection can have an asymptomatic course or it can present with fever, malaise and dry cough in the initial phase, during the invasion and infection of the upper respiratory tract. Patients may also experience gastrointestinal symptoms such as abdominal pain, vomiting and diarrhoea, and signs of systemic involvement (mainly neurological, cardiological, renal, and hepatological manifestations). Subsequently, the disease can involve the lower respiratory tract in approximately 20 % of the cases and,in most severe situations, it can culminate in acute respiratory distress syndrome. This condition is characterized by a surge in circulatory inflammatory cytokines [mainly interleukin (IL)-1 , IL-6 , IL-8 , tumor necrosis factor (TNF)-α], termed ‘cytokine storm’,which is responsible for the subsequent inflammation and lung injury[1 ,3].

    Treatments for COVID-19 change according to the disease severity: They include symptomatic and supportive therapy (such as oxygen supplementation, fluid resuscitation and vasopressors in case of septic shock), broad-spectrum antibiotics for prevention/management of secondary bacterial infections or sepsis, steroids if respiratory failure occurs, and prophylactic low molecular weight heparin in patients with moderate to severe disease because of the high risk of thromboembolism. The efficacy of antivirals (predominantly remdesivir and lopinavir/ritonavir combination),immunomodulatory drugs (including tocilizumab, chloroquine and hydroxychloroquine) and other treatments in reducing mortality and exacerbation of COVID-19 pneumonia is controversial and needs further evidence. However, these drugs are frequently used in clinical practice in the absence of any alternative[1].

    As in other infectious diseases, recovered patients often continue to suffer from various long-term sequelae involving the respiratory system, as dyspnoea and cough,as well as less defined disabling manifestations; the latter include neuropsychiatric sequelae such as fatigue, anxiety, depression, post-traumatic stress disorder and insomnia[3 -7]. It is still unknown whether these symptoms derive from the infection itself, from its general management (mainly medical therapies) or from the disease itself through mechanisms that have yet to be determined.

    As COVID-19 affects also the gastrointestinal tract, some sequelae may derive from a disequilibrium of the intestinal homeostasis, but current evidence is almost absent[5 ,8].

    In this review we hypothesised that the direct involvement of the gut and the one derived from COVID-19 -related circumstantial conditions can predispose to the development of irritable bowel syndrome (IBS). To support this idea, we analysed the mechanism through which SARS-CoV-2 perturbs the intestinal physiology in infected individuals, went through the physiopathology of IBS and finally considered the possible factors that can subsequently trigger IBS after the COVID-19 recovery. For this aim, PubMed and Google Scholar were searched using various combinations of the terms “SARS-CoV-2 ”, “COVID-19 ”, “gastrointestinal”, “gut”, “symptoms”,“irritable bowel syndrome”, “microbiota”, and “microbiome”. Subsequently, we selected the most pertinent articles in support of reasonable common factors between COVID-19 and IBS enhancement and summarised current evidence.

    GASTROINTESTINAL INVOLVEMENT OF COVID-19

    Gastrointestinal manifestations of COVID-19 can be present with variable incidence(40 %-50 %), and include mainly diarrhoea, nausea, anorexia, vomiting, abdominal pain and belching. These symptoms may arise even in the absence of respiratory involvement or may appear after the onset of respiratory symptoms[2 ,9 ,10]. SARSCoV-2 is also associated with other gastrointestinal symptoms. One of these include liver injury, which can manifest as increased serum aminotransferases, bilirubin and γglutamyl transferase[2 ,10]. Furthermore, elevated blood levels of amylase and lipase have been described, but a strict causality of pancreatic damage with SARS-CoV-2 infection has not been ascertained. Importantly, the drugs used to treat COVID-19 may also have impact on the gastrointestinal tract[11].

    Gastrointestinal involvement in COVID-19 may be due to the capacity of SARSCoV-2 to directly infect the intestinal tract: This hypothesis is supported by detection of the virus in enterocytes and in stool samples of affected patients, and also in faecal samples of individuals with negative nasopharyngeal tests[12 -14]. As previously mentioned, SARS-CoV-2 attaches to the ACE2 to enter into human cells and to infect the host. This receptor exists in two forms: The full-length mACE2 , which is located on cell membranes with a transmembrane anchor and an extracellular domain, and the sACE2 , a soluble form released into blood circulation. The N-terminal domain of the mACE2 is the target of the S protein of SARS-CoV-2 [15]. The S protein consists of two different subunits: The S1 , which binds to the cell receptors of the host, and the S2 ,which mediates the fusion of the viral and cell membranes[16]. Two transmembrane protease serines, TMPRSS2 and TMPRSS4 , are essential to cleave the S protein at S1 /S2 and S2 sites, to enhance the S fusogenic activity, the entry and replication of the virus in mature small intestinal enterocytes[17 ,18].

    The ACE2 is expressed in several tissues within the human body with specific localization on different cells, including enterocytes, renal tubules, gallbladder,cardiomyocytes, male reproductive cells, placental trophoblasts, ductal cells, eye,vasculature and others[15 ,19]. Concerning the digestive system, the expression of ACE2 gene is highest in the small intestine, but it is also present among other sites,such as colon, stomach, oesophagus, liver, biliary tract and pancreas[19 -22]. Specifically, this receptor is expressed in the muscularis mucosa and mucosa of the intestine, including the epithelial cells, cholangiocytes, hepatocytes, pancreatic ductal,acinar and islet cells, and in the gastrointestinal vasculature[11 ,23 ,24]. ACE2 seems to play a key role in the intestinal homeostasis and functions. Indeed, it can regulate the blood flow perfusion by increasing the vascular resistance (primarily the mesenteric vasculature). Moreover, it is possible that ACE2 is capable of enhancing the mucosal nitric oxide production, which regulates the properties of the epithelial barrier, and of modulating the ion transport and the paracellular permeability. It can also induce duodenal secretory responses of mucosal bicarbonate against the luminal acid from the stomach and stimulate sodium and water absorption. It seems plausible that ACE2 is involved in the relaxation of the gastrointestinal wall musculature. Nonetheless,current evidence suggests that ACE2 is involved in inflammation and immunomodulation, and in the pathophysiology of IBS for contributing to enhance low-grade inflammation in the enteric nerve plexa[24 ,25]. The ACE2 can also regulate the intestinal amino acid homeostasis and absorption, the production of antimicrobial peptides, the intestinal motility and the gut microbiota independently of the reninangiotensin system[24 ,26]. It is also reported that the deficiency of this receptor in a murine model of colitis leads to an increased susceptibility to intestinal inflammation.This effect seems to be mediated by an impaired epithelial immunity and induced dysbiosis, defined as the impairment of the diversity and function of intestinal microbes. This is suggested by the increased propensity to develop severe colitis after the faecal microbiota transplantation of an impaired intestinal microbiota from mice with genetic inactivation of ACE2 into germ-free wild-type animals[26]. Moreover,preclinical evidence indicates that ACE2 can impair the electrophysiological and synaptic functions of the neurons of the enteric nervous system, thus influencing the gastrointestinal motility, sensitivity and the pathways of inflammation[27].

    Overall, it is plausible that the impairment of bowel physiology by SARS-CoV-2 may derive from a dysregulation of all these ACE2 -mediated functions due to a competitive mechanism of the virus on this receptor or from a downregulation of its anti-inflammatory activity. Moreover, the gastrointestinal manifestations may arise from a direct cytopathic effect of the virus on the mucous epithelium, from a malabsorption secondary to the invasion of enterocytes, or from the triggered inflammatory response with plasma cells and lymphocytes infiltration in the intestinal lamina propria[2 ,28]. Accordingly, SARS-CoV-2 infection can be associated with microscopic bowel inflammation with infiltrating plasma cells and lymphocytes, and with interstitial edema in the lamina propria, as well as overt acute haemorrhagic colitis with endoscopically confirmed mucosal injury[28 ,29]. The hypothesis of intestinal inflammation is supported by the detection of significantly increased levels of faecal cytokines, as IL-8 , in COVID-19 patients when compared to uninfected controls[30]. Additionally, a significant number of patients (approximately 30 %-75 %),more frequently those with gastrointestinal manifestations, has elevated values of faecal calprotectin, a protein released by neutrophils of the intestinal mucosa[31]. The occurrence of diarrhoea seems also higher among patients with higher SARS-CoV-2 RNA loads in stool samples[30]. Finally, the presence of virus-specific immunoglobulin A (IgA) in faecal samples suggests that the gastrointestinal tract may be immunologically active during SARS-CoV-2 infection[30].

    It is likely that the gut homeostasis and the intestinal immunity play a major role in the pathogenesis of COVID-19 and in the enhancement of the systemic inflammation triggered by the SARS-CoV-2 infection, which is characterized by significantly higher serum IL-6 , IL-8 , IL-10 and TNF-α in severe cases[30]. Indeed, it is described that higher levels of faecal IL-23 correlate with more severe COVID-19 disease, as well as the finding of intestinal virus-specific IgA responses[30]. Interestingly, gut microbial alterations in COVID-19 patients can contribute to regulate systemic inflammation, as suggested by the correlation between specific changes in genera and inflammation indices[32].

    IBS

    IBS is the most common chronic disorder of the gut-brain interaction, and it is characterized by mild to severe recurrent abdominal pain and bloating associated to alterations in bowel habits in the absence of organic disease or biochemical abnormalities[33]. IBS is also often accompanied by other comorbidities, like psychiatric conditions, pain syndromes, overactive bladder, migraine, and visceral sensitivity[34]. The debilitating symptoms of IBS impose a significant burden on the quality of life of affected individuals, since it is associated with depression and suicidal ideation, reduces work productivity and increases the accesses to medical care[35 ,36].The prevalence of IBS varies substantially between countries due to the different diagnostic criteria and survey methods used in worldwide studies, ranging from less than 1 % to more than 25 %, with a predominance in women in comparison to men(12 .0 % vs 8 .6 % respectively; odds ratio 1 .46 )[37]. Moreover, it is more frequent in lower socioeconomic groups and individuals younger than 50 years[36]. IBS is diagnosed according to the Rome criteria, a clinical classification which includes four types of IBS according to the predominant bowel habits: IBS with predominant constipation, IBS with predominant diarrhoea (IBS-D), IBS with mixed bowel habits (IBS-M) and unclassified IBS[38]. IBS-M and IBS-D are reported to be the most prevalent subtypes[37]. For an accurate diagnosis of IBS, organic underlying conditions must be excluded, with an accurate patient history, physical examination, laboratory tests and, if necessary,endoscopic assessment. Common conditions which should be ruled out include celiac disease, microscopic colitis, inflammatory bowel disease, bile acid malabsorption,colorectal cancer, and dyssynergic defecation[38 ,39].

    The physiopathology of IBS is currently not fully understood, but it is considered a complex multifactorial disorder with a still unknown molecular pathophysiology.Indeed, it has been hypothesised that an impairment of different functions (such as central and autonomic neurophysiology, visceral nociception, bowel motility,secretory activity and psycho-somatic balance) due to perturbing factors (i.e., stress exposure, psychosocial conditions, food antigens, antibiotics and infections of various origin) leads to physiological abnormalities, which may be involved in the development and perpetuating of IBS. These include intestinal dysbiosis, increased intestinal permeability, immune cell hyper-reactivity with impaired expression and release of mucosal and immune mediators, microinflammation with altered mucosal functions, hyper-sensitivity of the enteric nervous system, dysregulation of the hypothalamus-pituitary-adrenal (HPA) axis and of the enteric nervous system.Increased levels of faecal bile acids and predisposing inheritable susceptibility are recognised as co-occurring factors as well[34 ,39 ,40]. Increasing evidence suggests that all these affected pathways are part of the microbiota-gut-brain axis, a bidirectional crosstalk between the brain, the bowel and the gut microbiota which occurs through nervous signalling, immune mediators, microbial products, tryptophan metabolites and other hormones[39 ,41].

    Accordingly, dysbiosis may contribute to IBS by triggering the gut immune system and enhancing low-grade inflammation in susceptible individuals. This hypothesis is supported by a higher prevalence of small intestinal bacterial overgrowth and imbalances of the gut microbiota composition in patients with IBS compared with healthy controls in many recent studies, and by the benefit from the use of nonabsorbable antibiotics on related symptoms. A reduction of the diversity and stability of the gut microbiota in patients with IBS has been described[42]. Increased Enterobacteriaceae, which includes several harmful genera (asEscherichia,Shigella,Campylobacter,andSalmonella), and Lactobacillaceae families, together with high levels ofBacteroidesgenus, reducedFaecalibacteriumandBifidobacteriumgenera and uncultured Clostridiales I are reported in patients with IBS in comparison with controls in a recent systematic review including 24 studies[43].

    In 6 %-17 % of the patients suffering with IBS the onset of the symptoms occurs after a recent episode of gastrointestinal infection, which can increase up to 6 -fold the risk of developing IBS. This phenomenon is characterised by the persistence of IBS-like disturbances (mainly diarrhoea and abdominal discomfort) after the resolution of the infection, and it is known as post-infectious IBS (PI-IBS). The prevalence of PI-IBS is approximately 4 %-36 % in patients with previous infectious gastroenteritis and is higher in females, young people, patients who experienced severe infections and individuals with psychological comorbidities. Moreover, some pathogens seem more predisposing than others; indeed, bacterial infections (particularly byCampylobacter,Shigella,Escherichia coliandSalmonella) are more likely to enhance PI-IBS than viruses and other microorganisms[34 ,44 ,45]. The pathogenesis of this condition is poorly understood, but it is hypothesized that the responsible pathogenic microorganism may trigger an immunologic and inflammatory response with low-grade inflammation and mucosal injury, which causes the prolongation of IBS symptoms in predisposed individuals. Furthermore, it is described that patients with PI-IBS may have increased macrophages and T lymphocytes in intestinal samples, together with high expression of IL-1 in rectal biopsies and elevated blood level pro-inflammatory cytokines (such as TNF-α, IL-6 , IL-8 , IL-10 and IL-1 β)[44 ,46]. As in IBS, it is likely that an altered intestinal permeability, an impairment of the gut eubiosis and of the neuromuscular function are involved in PI-IBS as well[47].

    COVID-19 AND ITS MANAGEMENT: WHAT ARE THE POSSIBLE TRIGGERS OF IBS?

    The plausible mechanisms involved in the development of IBS in individuals who experienced COVID-19 are summarised in Figure 1 .

    Gastrointestinal disturbances are often associated with respiratory infections or to secondary complications, and the gut-lung axis, a hypothetical bidirectional pathway which worksviabiochemical and immunologic systemic signalling molecules, is possibly involved in the pathophysiology. Among the perturbing factors of the gut microbial environment, respiratory viral infections, including COVID-19 , can play a relevant role[48]. As previously mentioned, an impairment of the gut microbiota composition, which is frequently associated to a dysregulation of the overall intestinal homeostasis and gut-brain axis, can participate to the development and maintaining of IBS[39 ,41 ,42]. An imbalance of the gut microbiota is described in SARS-CoV-2 -infected individuals. Guet al[32] found a significant reduction in mean community richness and bacterial diversity in COVID-19 patients in comparison with healthy controls according to the Shannon diversity index and Chao diversity index. A significantly higher relative abundance ofStreptococcus,Rothia,Veillonella, andActinomyces, which are opportunistic pathogens, and a lower relative abundance of beneficial symbionts were reported. Moreover,Fusicatenibacter,Romboutsia,Intestinibacter,Actinomycesand

    Erysipelatoclostridiumwere identified as biomarkers to discriminate the COVID-19 patients from healthy individuals[32]. Zuo et al[49] reported that even antibioticsunexposed patients with COVID-19 have a significantly changed intestinal microbiota during the hospitalization, with enrichment of opportunistic pathogens (including

    Clostridium hathewayi,Actinomyces viscosus, andBacteroides nordii) and depletion of beneficial commensals when compared to healthy individuals. Moreover, a correlation between the disease severity and the baseline abundance of certain genera and strains was found, suggesting that the gut microbiota may contribute to the systemic involvement in the immune system responses; specifically, a positive relation was observed withCoprobacillus,Clostridium ramosum, andClostridium hathewayi, while a negative association was described withFaecalibacterium prausnitzii. The loss of beneficial bacteria persisted even after a negative throat swab and the disease resolution, suggesting a persistent deleterious effect on the gut microbiota[49]. The same working group also observed that an active intestinal infection is present in approximately half of COVID-19 patients even without gastrointestinal manifestation,and persisted even after respiratory clearance of SARS-CoV-2 . Of interest, stool specimen with a signature of high SARS-CoV-2 infectivity were characterised by an enrichment of opportunistic pathogens (includingCollinsella aerofaciens,Collinsella tanakaei,Streptococcus infantisandMorganella morganii). On the other hand, faecal samples with a signature of “l(fā)ow-to-none” SARS-CoV-2 infectivity displayed higher concentration ofParabacteroides merdae,Bacteroides stercorisandLachnospiraceae bacterium 1_1 _57FAA. The latter are short-chain fatty acid producing bacteria, which play a crucial role in boosting host immunity. A longitudinal follow-up revealed relevant alterations of the faecal microbiota composition in a subset of patients[50].

    More generally, intestinal and pulmonary dysbiosis are described in various acute and chronic pulmonary diseases. For example, pulmonary viral infections, such as the ones caused by influenza virus and respiratory syncytial virus, can even directly impair the gut microbiome[49]. Moreover, patients suffering from asthma have functional and structural impairment of the intestinal mucosa, and patients with chronic obstructive pulmonary disease often have leaky gut[51]. Apart from the acute COVID-19 phase, respiratory sequelae and radiological abnormalities (such as dyspnoea, chronic cough, fibrotic lung disease, bronchiectasis, and pulmonary vascular disease) may persist in recovered patients, and the optimal management is still undefined[5 ,52 ,53]. Thus, it might be plausible that an impairment of the gut homeostasis may occur in patients during the acute COVID-19 illness and persist after the disease resolution, even in those who did not experience gastrointestinal disturbances. This can be hypothetically explained by the communication between the two systems through the gut-lung axis. The existence of this connection is not entirely understood, but it is strengthened by the occurrence of lung diseases worsening as a consequence to intestinal microbial imbalances, gut inflammation and increased intestinal permeability[54]. Accordingly, it is reported that elevated values of faecal calprotectin are associated with a pathological chest X ray in COVID-19 patients[55].Of interest, the enriched presence in faecal samples of patients with COVID-19 with high SARS-CoV-2 infectivity ofStreptococcus infantis, an upper respiratory tract and oral cavity colonizer bacterial pathogen, may indicate a translocation or transmission of extraintestinal microbes into the gut during COVID-19 [50]. Moreover, lung and gut are independent systems which originate from one common embryonic organ, the foregut[56]. The microbiota of these two systems develop almost simultaneously after birth and is influenced by common factors, such as diet[57]. Overall, it is possible that a COVID-19 -induced dysregulation of the gut-lung axis may enhance predisposing circumstances for IBS. This is also supported by the increased occurrence of gut disturbances, like inflammatory bowel disease or IBS, in patients with chronic respiratory diseases. Moreover, a pulmonary involvement has been described in approximately 33 % of patients with IBS[51].

    Figure 1 Possible pathophysiology of irritable bowel syndrome in coronavirus disease 2019 patients. ACE2 : Peptidase angiotensin receptor 2 ;COVID-19 : Coronavirus disease 2019 ; HPA: Hypothalamus-pituitary-adrenal; SARS-CoV-2 : Severe acute respiratory syndrome coronavirus-2 .

    As previously mentioned, viral enteritis is described as a risk factor for developing PI-IBS. This has been assessed for norovirus infections in particular. Porteret al[58]found a significant increase in the incidence of functional gastrointestinal disorders,including constipation, in individuals who experienced a gastroenteritis during a norovirus outbreak, suggesting that dysmotility-related disorders may arise from viral infections[58]. Previously, Marshall et al[59] described a significantly increased prevalence of PI-IBS in a small cohort of subjects after a large outbreak of acute gastroenteritis attributed to food-borne norovirus when compared to unexposed individuals (23 .6 % vs 3 .4 %, P = 0 .014 ), with OR of 6 .9 (95 %CI: 1 .0 -48 .7 )[59]. Similarly,an Italian study assessed the incidence of PI-IBS and functional gastrointestinal disorders after a norovirus outbreak. At 12 mo follow up a significant greater proportion of the infected participants (13 %, 40 of 186 adults) developed PI-IBS in comparison with unexposed controls (3 of 198 subjects). The mechanisms through which IBS is elicited by norovirus are unknown, but this micro-organism can lead to epithelial barrier dysfunction, increased intestinal permeability, reduction in villous surface area and villous height, and to a mucosal immune response with an increase of cytotoxic intra-epithelial T cells[47]. It is possible that these alterations may trigger a perpetual immune stimulation or a prolonged immune activation toward crossreacting non-pathogenic antigens, which impairs the gut sensory-motor function[58].Since SARS-CoV-2 can have an intestinal tropism and induce intestinal flogosis[13 ,30 ,31], it can be speculated that a mechanism similar to that of norovirus is involved in the enhancement of PI-IBS.

    Other non-infective factors may possibly play a key role in IBS pathophysiology. To date, COVID-19 management has involved a wide range of medications, whose efficacy has yet to be rigorously proven or is still under evaluation, and that can enhance a dysbiotic state. Above all, empiric antimicrobial use is often part of the treatment of respiratory infections, including SARS-CoV-2 [60]. It is well known that broad-spectrum antibiotics can cause a rapid and significant drop in taxonomic richness, diversity and evenness, that can persist even for years after the treatment interruption. Beyond taxonomical compositional alterations, the gene expression,protein activity and metabolism of the gut microbiota can be impaired by antibiotics.Overall, these changes can predispose to intestinal infections, to overgrowth and pathogenic behaviour of resident opportunistic organisms, and to impairment of the immunological equilibrium with systemic and long-term consequences[61]. Alongside with gut dysbiosis, broad-spectrum antibiotics can induce a disruption of the intestinal barrier function by altering the tight junction protein expression and localization,enhancing a pro-inflammatory state by NLRP3 inflammasome activation and promoting autophagy[62]. Hospitalised patients affected by COVID-19 are frequently treated with broad spectrum antibiotics for 5 -8 d, mainly to prevent or to treat pathogens causing atypical pneumonia and staphylococci[60]. For instance,azithromycin, which is largely prescribed to COVID-19 patients, can induce a decline in the microbial richness and diversity, as well as changes in microbiota composition,with a shift in the Actinobacteria phylum, a reduction in the relative abundance of Proteobacteria and Verrucomicrobia (includingAkkermansia muciniphila) and a decrease of the levels of bifidobacteria[63 ,64]. It is also reported that COVID-19 patients treated with vancomycin and/or ceftriaxone went through significant compositional alteration with reduced diversity of the gut microbiota[30].

    Additionally, it is described that the use of corticosteroids, which is considered a treatment option in severe COVID-19 cases, may induce dysbiosis and alter intestinal homeostasis as well[57 ,65]. This is supported by the influence of steroid hormones on the gut bacterial communities in animal studies. In example, gonadectomy can reduce the microbiota-related sex differences observed between male and female rats.Similarly, hormone replacement to rodent females from the birth can decreased the microbial diversity in adulthood by increasing the Firmicutes:Bacteroidetes ratio[66].As to systemic glucocorticoid therapy, there is evidence that subcutaneous prednisolone administration can alter the gut microbiota of mice, inducing significant shifts in the relative abundance of bacteria (decrease in Verrucomicobiales and Bacteriodales and increase in Clostridiales) in comparison with controls[67]. Interestingly, it is reported that individuals with glucocorticoid-induced obesity, who received prednisolone for at least three months, have significant decrease in gut microbial diversity in comparison with healthy controls, alongside with increased Firmicutes and Actinobacteria levels, and depletion in Bacteroidetes. Taxonomic analysis revealed a significantly reduced relative abundances ofBacteroides,Bifidobacterium, andEubacteriumin treated patients, whereasStreptococcusandGeobacillusdisplayed higher abundances. Also the faecal content of short-chain fatty acids (propionate and butyrate), which are products of carbohydrate fermentation by the gut bacteria, tended to be remarkably lower when compared to healthy control[68].

    Other treatment options for the pulmonary phase of COVID-19 include antiviral drugs, mainly the adenosine nucleotide analogue prodrug remdesivir and the protease inhibitor lopinavir in combination with ritonavir[69]. Multicentre randomized controlled trials to assess the efficacy in reducing inpatient mortality, ventilation rate,and duration of hospital stay are still undergoing, although preliminary results are overall not encouraging[70]. While remdesivir seems not to affect the gut microbiota composition, antiretrovirals may somehow have a modulatory activity. The knowledge of the impact of antiretroviral drugs on the microbiome is limited by little evidence and it is predominantly focused on human immunodeficiency virus (HIV)treatment. It is still unclear whether antiretroviral treatment can consistently restore gut health of HIV-infected individuals or not, but it is likely that the initiation and prosecution of these medications can promote dysbiotic states[71 ,72]. Importantly,there is evidence that this drug class can promote microbiome changes independently from those induced by HIV. Indeed, a decreased alpha diversity is reported among treated patients in comparison with untreated HIV-positive ones. Moreover, protease inhibitors can directly interfere with thein vitroadherence ofCandida albicansto an epithelial cell layer, which can possibly contribute to the reduction of oral candidiasis in HIV treated individuals[73].

    Even if current evidence discourages its use in the prevention or treatment of COVID-19 , hydroxychloroquine has been largely administered to patients due to its in-vitro capability of inhibiting SARS-CoV-2 by interfering with membrane fusion between host cell and the virus, especially in the early phase of the pandemic[70 ,74].Hydroxychloroquine was initially used as an antimalarial, but, subsequently, it has been used as a disease-modifying anti-rheumatic drug to treat rheumatic disorders due to its immunomodulatory properties[75]. The impact of this medication on the human gut microbiota has been assessed by Balmantet al[48] in patients affected by systemic lupus erythematosus. They reported that the use of this drug is associated to different degrees of dysbiosis with a dose-dependent effect[48].

    Severe SARS-CoV-2 infection is associated to an aberrant immune response with a massive cytokine release, mainly the IL-6 and IL-8 . The elevation of inflammatory markers, such as IL-6 and C-reactive protein, has been associated with mortality and severe disease with pulmonary involvement in comparison to moderate disease. Thus,the targeted blockade of systemic inflammation has been proposed as a strategy to treat advanced acute conditions with lung lesions when contrasting the virus alone might not be sufficient. Specifically, Tocilizumab, a monoclonal antibody that inhibits the IL-6 receptor, has been proposed in patients with advanced lung injury[69]. Little evidence about the effect of this biological agent on the intestinal microbiota is available. A study of patients with rheumatoid arthritis reported that biologics,including tocilizumab, significantly reduced the total bacterial count and led to a decrease ofClostridium coccoidesgroup,Bifidobacterium, andLactobacillus plantarumand

    Lactobacillus gasseristrains after 6 mo[76]. Furthermore, it has been hypothesized that the aetiology of tocilizumab-related intestinal perforation may lie in the compositional or functional microbial changes[8]. Possibly, another IL-6 receptor inhibitor, which is currently being tested for severe COVID-19 , may induce similar changes to the intestinal microbiota, but no study with this objective has been performed to date[69].

    A further significant imbalance in the commensal bacterial populations may also be caused by polypharmacotherapy (e.g.proton-pump inhibitors, laxatives and metformin), which is common especially in elderly comorbid COVID-19 patients, and by the use of commonly prescribed drugs to manage mild COVID-19 , as nonsteroidal anti-inflammatory drugs[63].

    Finally, another considerable element involved in the IBS onset, exacerbation and relapse, is the activation of the HPA axis consequential to the secretion of the corticotropin-releasing hormone due to acute or chronic stressful conditions. This signalling pathway affects the gut functions by regulating the stimulation of the sympathetic and parasympathetic activity, the release of catecholamines, the mucosal immunity, the intestinal barrier function, the splanchnic blood flow and the composition and growth of the gut microbiota. Immune activation and intestinal micro-inflammation are described in IBS and can increase the intestinal permeability, modulate the peripheral sensitization of mucosal neuronal afferents and the recruitment of “silent” nociceptors involved in the hypersensitivity. Similarly, stress-induced dysbiosis may modulate the neuro-immune-endocrine systems and interfere with the brain-gut axis. Accordingly,the prevalence of at least one psychiatric disorder (mainly depression and anxiety) in patients with IBS ranges from 40 % to 60 % approximately, and the severity of IBS manifestations is remarkably correlated with the intensity co-morbid psychiatric disturbs. Moreover, early adverse life events and major traumatic experiences are frequently described before the onset of IBS[77 ,78]. COVID-19 is having a significant impact on mental health worldwide, since various psychological stress-associated factors are linked to the pandemic. More than 40 % of patients experiences psychological distress even when the disease is under control during the acute infection phase. A considerable role is also played by anxiety, panic and fear for the isolation environment and the uncertain sequelae following resolution of a new and dangerous disease. Long-term psychological consequences (as anxiety, depression, post-traumatic stress disorder, insomnia, irritability, memory impairment, fatigue, and traumatic memories) are frequently reported among those who suffered from COVID-19 ,especially hospitalized ones and individuals with previous emotional dysregulation[7 ,79]. Overall, COVID-19 -related psychological disturbances are significant and can definitely contribute to IBS occurrence.

    CONCLUSION

    The COVID-19 pandemic is a threat to global public health. A wide spectrum of respiratory and systemic symptoms can occur during the acute disease with different degrees of severity, and some of them can persist over time after the recovery. A large body of evidence supports the gastrointestinal involvement of SARS-CoV-2 infection during the acute phase, possibly because the intestinal ACE2 is an additional target of viral infection. Importantly, little is known about the gastrointestinal sequelae; at present, there is no study reporting the occurrence of IBS in individuals recovered from COVID-19 . However, a number of considerations may be made regarding the plausible role of COVID-19 , its management and global setting in the enhancement of IBS. Specifically, it can be assumed that many factors contributing to promote a dysbiotic state, epithelial barrier impairment, intestinal inflammation and gut dysfunction (like antibiotics and other treatments of the acute phase, gut-lung axis impairment, disease-related psychological stress, as well as the virus itself) can be involved in this process. Prospective cohort studies are necessary to confirm these hypotheses before clinical significance can be concluded.

    老熟妇仑乱视频hdxx| 亚洲情色 制服丝袜| 亚洲精品久久午夜乱码| 手机成人av网站| 悠悠久久av| 午夜福利视频在线观看免费| 天天添夜夜摸| 久久久国产成人免费| 成年女人毛片免费观看观看9 | 欧美97在线视频| 在线精品无人区一区二区三| 十八禁网站免费在线| 99久久人妻综合| 亚洲精品在线美女| 丰满饥渴人妻一区二区三| 91成人精品电影| 久久国产精品大桥未久av| 日韩欧美一区视频在线观看| 久久精品亚洲熟妇少妇任你| 天天躁夜夜躁狠狠躁躁| 在线天堂中文资源库| 老熟女久久久| 色婷婷久久久亚洲欧美| 亚洲中文日韩欧美视频| 精品卡一卡二卡四卡免费| 亚洲精品国产av成人精品| 超碰成人久久| a级毛片黄视频| 精品高清国产在线一区| 青春草亚洲视频在线观看| 2018国产大陆天天弄谢| 成人三级做爰电影| www.熟女人妻精品国产| 777米奇影视久久| 久久久精品94久久精品| 亚洲精品国产一区二区精华液| 日韩人妻精品一区2区三区| 老鸭窝网址在线观看| 十八禁人妻一区二区| 日本a在线网址| 黑丝袜美女国产一区| 亚洲男人天堂网一区| 国产欧美日韩精品亚洲av| 女人久久www免费人成看片| 人成视频在线观看免费观看| 国产欧美日韩一区二区精品| 少妇的丰满在线观看| 成人国语在线视频| 18禁黄网站禁片午夜丰满| 亚洲欧美成人综合另类久久久| 欧美人与性动交α欧美精品济南到| 国产成人一区二区三区免费视频网站| 亚洲国产av影院在线观看| 三级毛片av免费| 免费高清在线观看视频在线观看| 亚洲av日韩精品久久久久久密| 女人高潮潮喷娇喘18禁视频| 黄色视频在线播放观看不卡| 1024香蕉在线观看| 黄色毛片三级朝国网站| 美女主播在线视频| 一区二区三区乱码不卡18| 两人在一起打扑克的视频| 欧美精品人与动牲交sv欧美| 老汉色av国产亚洲站长工具| 自拍欧美九色日韩亚洲蝌蚪91| 亚洲人成电影免费在线| av超薄肉色丝袜交足视频| 青草久久国产| 久久香蕉激情| 中文字幕色久视频| 国产一区二区 视频在线| 免费av中文字幕在线| 亚洲美女黄色视频免费看| 免费高清在线观看日韩| 另类亚洲欧美激情| 欧美日韩中文字幕国产精品一区二区三区 | 超碰成人久久| 九色亚洲精品在线播放| 一二三四在线观看免费中文在| 国精品久久久久久国模美| 首页视频小说图片口味搜索| 最近最新免费中文字幕在线| 欧美激情极品国产一区二区三区| 国产精品 国内视频| 免费在线观看黄色视频的| 黄片大片在线免费观看| 新久久久久国产一级毛片| 熟女少妇亚洲综合色aaa.| 一二三四社区在线视频社区8| 黑人操中国人逼视频| 1024视频免费在线观看| 老熟妇仑乱视频hdxx| 老司机福利观看| 日本精品一区二区三区蜜桃| 亚洲av成人一区二区三| 人成视频在线观看免费观看| 久久久久久人人人人人| 性少妇av在线| 两性午夜刺激爽爽歪歪视频在线观看 | 激情视频va一区二区三区| 我的亚洲天堂| 三上悠亚av全集在线观看| 日本精品一区二区三区蜜桃| 91九色精品人成在线观看| 国产精品久久久久久人妻精品电影 | 久久精品aⅴ一区二区三区四区| 一级毛片女人18水好多| 狠狠婷婷综合久久久久久88av| 秋霞在线观看毛片| 亚洲国产av新网站| 午夜免费观看性视频| 国产av国产精品国产| 99国产精品一区二区蜜桃av | 18禁观看日本| 国产成人啪精品午夜网站| 在线天堂中文资源库| 亚洲一区中文字幕在线| 最新的欧美精品一区二区| 国产在线一区二区三区精| 多毛熟女@视频| 成人亚洲精品一区在线观看| 下体分泌物呈黄色| 18禁黄网站禁片午夜丰满| 欧美变态另类bdsm刘玥| 国产成人a∨麻豆精品| 免费一级毛片在线播放高清视频 | 日韩大码丰满熟妇| 亚洲精品一区蜜桃| 亚洲欧洲精品一区二区精品久久久| 欧美日本中文国产一区发布| 亚洲自偷自拍图片 自拍| 国产色视频综合| av在线老鸭窝| 亚洲欧美日韩高清在线视频 | 国产日韩欧美亚洲二区| 国产高清videossex| 国产av精品麻豆| 久久久精品区二区三区| 老司机福利观看| 午夜福利免费观看在线| 亚洲欧美日韩另类电影网站| 久久久久久亚洲精品国产蜜桃av| 亚洲久久久国产精品| 亚洲国产精品成人久久小说| 人人妻人人澡人人看| 久久久欧美国产精品| 大片免费播放器 马上看| 一进一出抽搐动态| 蜜桃在线观看..| www日本在线高清视频| 18禁黄网站禁片午夜丰满| 两个人免费观看高清视频| 精品第一国产精品| 男女床上黄色一级片免费看| 色老头精品视频在线观看| 日本wwww免费看| 精品人妻熟女毛片av久久网站| 一级黄色大片毛片| 午夜久久久在线观看| 狠狠狠狠99中文字幕| 国产成人av激情在线播放| 91av网站免费观看| 中文字幕人妻丝袜一区二区| 狠狠狠狠99中文字幕| 日韩大码丰满熟妇| 免费观看av网站的网址| 人人妻人人澡人人爽人人夜夜| 亚洲久久久国产精品| 免费在线观看完整版高清| 一二三四社区在线视频社区8| 婷婷色av中文字幕| 淫妇啪啪啪对白视频 | 麻豆国产av国片精品| 亚洲,欧美精品.| 少妇 在线观看| 国产高清videossex| 亚洲av欧美aⅴ国产| 国产又爽黄色视频| 国产成人a∨麻豆精品| 日本一区二区免费在线视频| 中国国产av一级| 午夜91福利影院| 国产精品99久久99久久久不卡| 亚洲午夜精品一区,二区,三区| 午夜福利视频精品| 制服人妻中文乱码| 免费av中文字幕在线| www.熟女人妻精品国产| 久久精品国产亚洲av高清一级| 国产一区有黄有色的免费视频| 国产亚洲精品一区二区www | 亚洲情色 制服丝袜| 大香蕉久久成人网| 亚洲第一青青草原| 亚洲熟女毛片儿| 两个人看的免费小视频| 丝袜人妻中文字幕| 亚洲视频免费观看视频| 日韩中文字幕欧美一区二区| 久久午夜综合久久蜜桃| 久久精品成人免费网站| 另类亚洲欧美激情| 久久久水蜜桃国产精品网| 国产色视频综合| 久久久久精品人妻al黑| 亚洲精品在线美女| 高潮久久久久久久久久久不卡| tocl精华| 在线天堂中文资源库| 午夜精品国产一区二区电影| av国产精品久久久久影院| 日本一区二区免费在线视频| 一个人免费在线观看的高清视频 | tube8黄色片| 男人爽女人下面视频在线观看| 人妻久久中文字幕网| 51午夜福利影视在线观看| 美女午夜性视频免费| 亚洲一区中文字幕在线| 一级毛片电影观看| 丝袜人妻中文字幕| 十八禁网站免费在线| 亚洲专区中文字幕在线| netflix在线观看网站| 久久久久视频综合| 老鸭窝网址在线观看| 亚洲,欧美精品.| 每晚都被弄得嗷嗷叫到高潮| 午夜福利视频精品| 十分钟在线观看高清视频www| 黄频高清免费视频| 一区福利在线观看| 性色av一级| 男男h啪啪无遮挡| 亚洲成国产人片在线观看| 天天操日日干夜夜撸| 在线永久观看黄色视频| 亚洲精品中文字幕在线视频| 亚洲中文日韩欧美视频| 亚洲第一欧美日韩一区二区三区 | 在线十欧美十亚洲十日本专区| √禁漫天堂资源中文www| 国产福利在线免费观看视频| 国产真人三级小视频在线观看| 亚洲精品一卡2卡三卡4卡5卡 | 99国产精品99久久久久| 亚洲成国产人片在线观看| 免费高清在线观看视频在线观看| 女性生殖器流出的白浆| 精品视频人人做人人爽| 久久亚洲精品不卡| 久久久精品94久久精品| 欧美日韩视频精品一区| 性色av乱码一区二区三区2| 亚洲精品一二三| 日本五十路高清| 少妇 在线观看| 99久久综合免费| 国产精品 欧美亚洲| 亚洲人成电影免费在线| 人成视频在线观看免费观看| 日本黄色日本黄色录像| 亚洲第一av免费看| 欧美 日韩 精品 国产| 成年人午夜在线观看视频| 黄色a级毛片大全视频| 中文字幕色久视频| 亚洲一卡2卡3卡4卡5卡精品中文| 国产精品免费大片| 午夜91福利影院| 妹子高潮喷水视频| 少妇 在线观看| 丝袜美足系列| 搡老乐熟女国产| 欧美黄色淫秽网站| 丁香六月欧美| 夜夜骑夜夜射夜夜干| 国精品久久久久久国模美| 精品国内亚洲2022精品成人 | 国产精品1区2区在线观看. | 黑人操中国人逼视频| 午夜免费鲁丝| 精品一区在线观看国产| 少妇的丰满在线观看| 免费在线观看黄色视频的| 亚洲精品日韩在线中文字幕| 丝袜美腿诱惑在线| 岛国毛片在线播放| 国产免费av片在线观看野外av| 在线观看人妻少妇| 蜜桃国产av成人99| 久久亚洲国产成人精品v| 亚洲av欧美aⅴ国产| 国产成人一区二区三区免费视频网站| 午夜激情久久久久久久| 亚洲色图综合在线观看| 色老头精品视频在线观看| 中文字幕制服av| 日韩视频在线欧美| 亚洲欧美一区二区三区黑人| 99精国产麻豆久久婷婷| 国产精品.久久久| 高清视频免费观看一区二区| 亚洲视频免费观看视频| 亚洲第一av免费看| 亚洲精品一区蜜桃| 亚洲国产欧美日韩在线播放| 曰老女人黄片| 国产精品久久久久成人av| 少妇猛男粗大的猛烈进出视频| 久久综合国产亚洲精品| 婷婷丁香在线五月| 两人在一起打扑克的视频| 精品熟女少妇八av免费久了| 一区二区三区精品91| 久久久久国内视频| 交换朋友夫妻互换小说| 性高湖久久久久久久久免费观看| 亚洲男人天堂网一区| 国产精品国产av在线观看| 亚洲欧美精品综合一区二区三区| 久久人人爽av亚洲精品天堂| 色精品久久人妻99蜜桃| 久久亚洲国产成人精品v| 日韩电影二区| 国产精品麻豆人妻色哟哟久久| 亚洲 国产 在线| 亚洲精品国产区一区二| 亚洲成人免费电影在线观看| 免费在线观看视频国产中文字幕亚洲 | 国产精品一区二区在线不卡| 2018国产大陆天天弄谢| 一本—道久久a久久精品蜜桃钙片| 亚洲一卡2卡3卡4卡5卡精品中文| 国产一区二区三区av在线| 中亚洲国语对白在线视频| 男女免费视频国产| 狠狠婷婷综合久久久久久88av| 免费高清在线观看日韩| 视频区欧美日本亚洲| 大香蕉久久网| www.av在线官网国产| 国产一区二区三区综合在线观看| 蜜桃在线观看..| 国产又色又爽无遮挡免| 一区福利在线观看| 精品国产一区二区三区四区第35| 一个人免费看片子| 91成人精品电影| 国产一区有黄有色的免费视频| 新久久久久国产一级毛片| av天堂在线播放| 波多野结衣av一区二区av| 国产精品影院久久| 日韩欧美国产一区二区入口| 成年av动漫网址| 国产深夜福利视频在线观看| 99久久人妻综合| 人人妻,人人澡人人爽秒播| 99国产极品粉嫩在线观看| 日韩欧美国产一区二区入口| av线在线观看网站| av线在线观看网站| av在线app专区| 97在线人人人人妻| www.自偷自拍.com| 黑人巨大精品欧美一区二区蜜桃| 嫩草影视91久久| av在线app专区| 巨乳人妻的诱惑在线观看| 国产在线观看jvid| 在线观看一区二区三区激情| 国产日韩欧美亚洲二区| 丁香六月天网| 国产亚洲av片在线观看秒播厂| 丁香六月天网| 欧美精品高潮呻吟av久久| av在线老鸭窝| 日韩视频在线欧美| 一区福利在线观看| 美女中出高潮动态图| 精品一品国产午夜福利视频| 美女午夜性视频免费| 久久狼人影院| 80岁老熟妇乱子伦牲交| 亚洲视频免费观看视频| 精品乱码久久久久久99久播| 亚洲成av片中文字幕在线观看| 久久毛片免费看一区二区三区| 亚洲成人国产一区在线观看| 日本精品一区二区三区蜜桃| 亚洲国产日韩一区二区| 欧美日韩中文字幕国产精品一区二区三区 | 50天的宝宝边吃奶边哭怎么回事| 人人妻人人添人人爽欧美一区卜| 日日摸夜夜添夜夜添小说| 亚洲精品av麻豆狂野| 国产精品亚洲av一区麻豆| av网站免费在线观看视频| 免费在线观看完整版高清| 18禁观看日本| 欧美精品啪啪一区二区三区 | 午夜激情久久久久久久| 午夜福利视频精品| 精品久久久精品久久久| 色老头精品视频在线观看| 亚洲专区国产一区二区| 亚洲欧美日韩另类电影网站| 国产亚洲av高清不卡| 亚洲精品第二区| 一本综合久久免费| 久久精品成人免费网站| 亚洲美女黄色视频免费看| 中文字幕人妻熟女乱码| 夜夜夜夜夜久久久久| www.精华液| 窝窝影院91人妻| 美国免费a级毛片| 少妇 在线观看| 亚洲 国产 在线| 亚洲国产看品久久| 99精品欧美一区二区三区四区| 国产三级黄色录像| 国产成人精品无人区| 制服诱惑二区| 午夜日韩欧美国产| h视频一区二区三区| 男女下面插进去视频免费观看| 国产精品亚洲av一区麻豆| 女人爽到高潮嗷嗷叫在线视频| 精品亚洲乱码少妇综合久久| 亚洲人成77777在线视频| 亚洲色图 男人天堂 中文字幕| 黄色怎么调成土黄色| 丝袜喷水一区| 成人手机av| 高清在线国产一区| 国产精品久久久久成人av| 久久久久久久大尺度免费视频| 午夜福利乱码中文字幕| 亚洲av日韩精品久久久久久密| 久久免费观看电影| 国产97色在线日韩免费| xxxhd国产人妻xxx| 亚洲精品一卡2卡三卡4卡5卡 | 亚洲国产看品久久| 久久女婷五月综合色啪小说| 免费高清在线观看视频在线观看| 亚洲精品乱久久久久久| 日韩有码中文字幕| 夜夜夜夜夜久久久久| 亚洲av电影在线观看一区二区三区| 人妻人人澡人人爽人人| 超碰97精品在线观看| 久久国产精品男人的天堂亚洲| 捣出白浆h1v1| 99国产精品一区二区蜜桃av | 欧美大码av| 免费日韩欧美在线观看| 黑人巨大精品欧美一区二区蜜桃| 亚洲,欧美精品.| 99国产精品一区二区蜜桃av | 精品高清国产在线一区| 激情视频va一区二区三区| 精品一品国产午夜福利视频| 国产精品av久久久久免费| 久9热在线精品视频| 免费av中文字幕在线| 欧美 亚洲 国产 日韩一| 久久久久久人人人人人| 国产伦理片在线播放av一区| 美女大奶头黄色视频| 狂野欧美激情性xxxx| 王馨瑶露胸无遮挡在线观看| 欧美 日韩 精品 国产| 免费在线观看完整版高清| 久久久久久久久久久久大奶| 亚洲精品乱久久久久久| 精品卡一卡二卡四卡免费| 国产欧美日韩一区二区三区在线| 久久天堂一区二区三区四区| 狠狠狠狠99中文字幕| 菩萨蛮人人尽说江南好唐韦庄| 人人妻人人添人人爽欧美一区卜| 亚洲欧美精品综合一区二区三区| 欧美av亚洲av综合av国产av| 国产精品一区二区在线观看99| 精品国产乱码久久久久久小说| 亚洲av电影在线观看一区二区三区| 国产精品久久久久久精品电影小说| 国产亚洲精品第一综合不卡| 视频区欧美日本亚洲| 亚洲天堂av无毛| 制服人妻中文乱码| 狂野欧美激情性bbbbbb| 欧美97在线视频| 久久人妻福利社区极品人妻图片| 日本一区二区免费在线视频| 日本av手机在线免费观看| 亚洲精品成人av观看孕妇| 男女无遮挡免费网站观看| 国产伦人伦偷精品视频| 操美女的视频在线观看| 99国产精品99久久久久| 纯流量卡能插随身wifi吗| 黄色视频不卡| 国产欧美日韩综合在线一区二区| 国精品久久久久久国模美| 悠悠久久av| 大香蕉久久网| 亚洲av日韩在线播放| 大码成人一级视频| 男人爽女人下面视频在线观看| 亚洲国产看品久久| 91av网站免费观看| 久久久久国产一级毛片高清牌| 免费在线观看视频国产中文字幕亚洲 | 免费黄频网站在线观看国产| 狠狠婷婷综合久久久久久88av| 国产精品亚洲av一区麻豆| 免费在线观看视频国产中文字幕亚洲 | 男人添女人高潮全过程视频| 最近最新中文字幕大全免费视频| 十分钟在线观看高清视频www| 日韩免费高清中文字幕av| 丝袜喷水一区| 日本a在线网址| 熟女少妇亚洲综合色aaa.| a 毛片基地| 国产不卡av网站在线观看| 汤姆久久久久久久影院中文字幕| 搡老乐熟女国产| 999久久久精品免费观看国产| 一二三四社区在线视频社区8| 美女主播在线视频| 黄色怎么调成土黄色| 999久久久国产精品视频| 亚洲人成77777在线视频| 亚洲伊人久久精品综合| 在线观看舔阴道视频| 国产成人系列免费观看| 久久人妻熟女aⅴ| 国产精品免费大片| 黑人巨大精品欧美一区二区mp4| 午夜福利,免费看| 国产极品粉嫩免费观看在线| 精品国产国语对白av| 午夜福利视频在线观看免费| 亚洲国产欧美一区二区综合| 久久热在线av| 成年av动漫网址| 香蕉丝袜av| 一级毛片电影观看| 老熟妇仑乱视频hdxx| 免费高清在线观看视频在线观看| 国产无遮挡羞羞视频在线观看| 午夜福利在线观看吧| 不卡av一区二区三区| 久久精品人人爽人人爽视色| 成人18禁高潮啪啪吃奶动态图| 美女午夜性视频免费| 少妇人妻久久综合中文| 免费在线观看影片大全网站| 亚洲精品日韩在线中文字幕| 高清欧美精品videossex| 欧美激情 高清一区二区三区| 日本撒尿小便嘘嘘汇集6| 精品少妇一区二区三区视频日本电影| 国产欧美亚洲国产| 亚洲精品国产一区二区精华液| 亚洲国产欧美日韩在线播放| 男女之事视频高清在线观看| 黄片播放在线免费| av在线老鸭窝| 中文欧美无线码| 超碰成人久久| 亚洲精品美女久久av网站| 中文精品一卡2卡3卡4更新| 亚洲精品在线美女| 狠狠婷婷综合久久久久久88av| 欧美久久黑人一区二区| 丝袜喷水一区| 一区在线观看完整版| 国产老妇伦熟女老妇高清| 久久久水蜜桃国产精品网| 法律面前人人平等表现在哪些方面 | 天天躁狠狠躁夜夜躁狠狠躁| 精品一区二区三区四区五区乱码| 久久久久久久大尺度免费视频| 国产精品 国内视频| av国产精品久久久久影院| 考比视频在线观看| 2018国产大陆天天弄谢| 搡老岳熟女国产| 中文字幕色久视频| tube8黄色片| 日韩中文字幕视频在线看片| 国产成人系列免费观看| 一区二区av电影网| 性色av一级| 老鸭窝网址在线观看| 亚洲欧美一区二区三区久久| 国产精品二区激情视频| 亚洲综合色网址| 男人舔女人的私密视频| 欧美日韩成人在线一区二区| 老司机亚洲免费影院| 人人妻人人澡人人爽人人夜夜| 精品第一国产精品| 午夜免费观看性视频| 十分钟在线观看高清视频www| 少妇粗大呻吟视频| 免费高清在线观看视频在线观看| www日本在线高清视频|